On June 2, 2024, Caribou issued a press release announcing that it had “presented updated clinical data from the ongoing ANTLER Phase 1 trial that [purportedly] indicates a single dose of CB-010 . . .
NEW YORK/LONDON (Reuters) -Global markets are set for a fresh jolt on Monday after U.S. President Donald Trump launched a ...